New hope for kids with tough cancers: entrectinib trial underway
NCT ID NCT02650401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specific gene changes. About 69 children are taking part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- entrectinib
- What this could lead to
- If it works, this could provide a new treatment option for children with certain hard-to-treat cancers that have specific gene changes.
- What could go wrong
- This is an early-phase trial with only 69 participants, so results may not apply to all children. The drug may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CNS TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, China
-
Centre Leon Berard
Lyon, 69373, France
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Egleston Children's Hospital at Emory University Atlanta
Atlanta, Georgia, 30322, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
Hong Kong Children's Hospital
Hong Kong, 00000, Hong Kong
-
Hospital Infantil Universitario Nino Jesus
Madrid, 28009, Spain
-
Hôpital de la Timone, Oncologie Pédiatrique
Marseille, 13385, France
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Oregon Health & Science Uni
Portland, Oregon, 97239, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Royal Marsden Hospital (Sutton)
London, SW3 6JJ, United Kingdom
-
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
-
St. Jude Children'S Research Hospital
Memphis, Tennessee, 38105, United States
-
Texas Children's Cancer and Hematology Center
Houston, Texas, 77030, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
UCSF Benioff Children's Hospital
San Francisco, California, 94158, United States
-
Universitaetsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69120, Germany
-
University of California San Diego
La Jolla, California, 92093-0706, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Washington University,St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
-
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200082, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test